Get startedLog in
    Picture of Rafael Holdings logo

    RFL — Rafael Holdings News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapNeutral
    All News

    Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs

    Picture of Rafael Holdings logoRafael Holdings
    16/03/2026 20:12
    Overview

U.S. biotechnology firm's fiscal Q2 revenue rose yr/yr but remains modest

Net loss widened to $6.4 mln due to consolidation of Cyclo Therapeutic’s expenses after Cyclo acquisition

Company expects top-line results from pivotal Phase 3 trial in Q3 calendar 2026

Outlook

Company expects to complete 96-week Phase 3 Trappsol Cyclo trial and report top-line results in Q3 2026

Result Drivers

CYLO ACQUISITION IMPACT - Higher net loss and R&D expenses driven by consolidation of Cyclo Therapeutic's costs after March 2025 acquisition

LOWER ADMIN COSTS - General and administrative expenses fell due to reduced payroll and professional fees, partly offset by Cyclo expenses

Company press release: ID:nGNX8L5Qhc

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q2 Product Revenue$125,000
    Q2 Net Income-$6.33 mln
    Q2 Operating Income-$6.66 mln
    

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Rafael Holdings

    See all news